U.S. flag

An official website of the United States government

NM_000059.4(BRCA2):c.7165A>T (p.Arg2389Ter) AND Breast-ovarian cancer, familial, susceptibility to, 2

Germline classification:
Pathogenic (1 submission)
Last evaluated:
May 27, 2024
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV004556993.1

Allele description [Variation Report for NM_000059.4(BRCA2):c.7165A>T (p.Arg2389Ter)]

NM_000059.4(BRCA2):c.7165A>T (p.Arg2389Ter)

Gene:
BRCA2:BRCA2 DNA repair associated [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
13q13.1
Genomic location:
Preferred name:
NM_000059.4(BRCA2):c.7165A>T (p.Arg2389Ter)
HGVS:
  • NC_000013.11:g.32355018A>T
  • NG_012772.3:g.44539A>T
  • NM_000059.4:c.7165A>TMANE SELECT
  • NM_001406719.1:c.7069A>T
  • NM_001406720.1:c.7165A>T
  • NM_001406721.1:c.2233A>T
  • NM_001406722.1:c.748A>T
  • NP_000050.2:p.Arg2389Ter
  • NP_000050.3:p.Arg2389Ter
  • NP_001393648.1:p.Arg2357Ter
  • NP_001393649.1:p.Arg2389Ter
  • NP_001393650.1:p.Arg745Ter
  • NP_001393651.1:p.Arg250Ter
  • LRG_293t1:c.7165A>T
  • LRG_293:g.44539A>T
  • LRG_293p1:p.Arg2389Ter
  • NC_000013.10:g.32929155A>T
  • NM_000059.3:c.7165A>T
  • NR_176251.1:n.7364A>T
Protein change:
R2357*
Molecular consequence:
  • NR_176251.1:n.7364A>T - non-coding transcript variant - [Sequence Ontology: SO:0001619]
  • NM_000059.4:c.7165A>T - nonsense - [Sequence Ontology: SO:0001587]
  • NM_001406719.1:c.7069A>T - nonsense - [Sequence Ontology: SO:0001587]
  • NM_001406720.1:c.7165A>T - nonsense - [Sequence Ontology: SO:0001587]
  • NM_001406721.1:c.2233A>T - nonsense - [Sequence Ontology: SO:0001587]
  • NM_001406722.1:c.748A>T - nonsense - [Sequence Ontology: SO:0001587]

Condition(s)

Name:
Breast-ovarian cancer, familial, susceptibility to, 2 (BROVCA2)
Synonyms:
Breast-ovarian cancer, familial 2
Identifiers:
MONDO: MONDO:0012933; MedGen: C2675520; Orphanet: 145; OMIM: 612555

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV005045913Department of Clinical Genetics, Copenhagen University Hospital, Rigshospitalet
criteria provided, single submitter

(ACMG Guidelines, 2015)
Pathogenic
(May 27, 2024)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineyesnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Laboratory Quality Assurance Committee..

Genet Med. 2015 May;17(5):405-24. doi: 10.1038/gim.2015.30. Epub 2015 Mar 5.

PubMed [citation]
PMID:
25741868
PMCID:
PMC4544753

Details of each submission

From Department of Clinical Genetics, Copenhagen University Hospital, Rigshospitalet, SCV005045913.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)

Description

PVS1; PM2_supporting; PM5_PTC_Strong

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineyesnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Jun 2, 2024